ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

25.31 7.02

Overview

Share price change

24h

Current

Min

24.99

Max

27.25

Key metrics

By Trading Economics

Income

-270M

3.6M

Sales

-16M

268M

P/E

Sector Avg

9.996

50.958

EPS

0.02

Profit margin

1.357

Employees

796

EBITDA

-19M

7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+27.09% upside

Dividends

By Acuity

Next Earnings

5 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-17M

3.8B

Previous open

18.29

Previous close

25.31

News Sentiment

By Acuity

33%

67%

68 / 342 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Jun 2026, 23:51 UTC

News

iShares 20+ Year Treasury Bond ETF declines in after-market trading amid heightened geopolitical tensions from military actions in the Middle East.

26 Jun 2026, 23:41 UTC

News

Charter Communications is in talks with SpaceX for a partnership to enhance mobile services using Starlink, with shares trading higher in after-market hours.

26 Jun 2026, 23:31 UTC

Social Media
News

Barclays raised its price target for Micron Technology, citing strong earnings and AI demand. Shares are higher in after-market trading alongside broader market gains.

26 Jun 2026, 23:26 UTC

Social Media
News
ETF Constituents

Invesco QQQ Trust gains in after-market trading as retail sentiment turns bullish, contrasting with declines in the broader market amid tech sell-off.

26 Jun 2026, 23:16 UTC

Social Media
News

Amazon's stock rises after AWS announces a notable price increase in Nvidia compute services. Wells Fargo maintains a Buy rating and sets a target of $312.

26 Jun 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

26 Jun 2026, 23:02 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, supported by gains from top holdings and the Dow's third consecutive weekly increase.

26 Jun 2026, 23:02 UTC

Social Media
ETF Constituents
News

SPDR S&P 500 ETF Trust rises in after-market trading following S&P's affirmation of U.S. sovereign ratings, reflecting positive economic growth expectations.

26 Jun 2026, 23:02 UTC

Social Media
News

The United States Oil Fund LP rose after military strikes in the Strait of Hormuz heightened concerns over oil supply stability and increased trading activity.

26 Jun 2026, 23:02 UTC

Social Media
News

Fox Corp shares are trading lower in after-market hours, despite strong preliminary viewership for the USA vs. Turkiye World Cup match and merger discussions.

26 Jun 2026, 23:01 UTC

News

Fox Corp shares are lower in after-market trading amid broader market concerns over inflation and weakening momentum in AI-driven stocks, despite strong viewership for FIFA matches.

26 Jun 2026, 20:15 UTC

News
Correlated Moves
ETF Constituents

Vanguard Large-Cap ETF trades lower in after-market hours, reflecting declines in major holdings and a drop in the S&P 500 Index.

26 Jun 2026, 20:07 UTC

Correlated Moves
News
Macro Event

Bitcoin is higher today, reflecting a slight gain since Thursday's close. The Goods Trade Balance widened to a record deficit of $105.8 billion.

26 Jun 2026, 20:07 UTC

Macro Event
News
Correlated Moves

Bitcoin is higher during Friday's session, reflecting a slight gain since Thursday. Broader market sentiment appears to influence both Bitcoin and Ethereum.

26 Jun 2026, 20:06 UTC

Correlated Moves
News

The US dollar's decline pressures USD/SGD, which has traded lower since Thursday. Broader inflation concerns are influencing the asset's performance today.

26 Jun 2026, 20:06 UTC

News

The USD/NOK is higher today, supported by recent currency market dynamics. The US dollar declines amid falling oil prices and weak technology shares.

26 Jun 2026, 20:05 UTC

Social Media
News

Tesla Inc. shares are higher, supported by a report showing 15.78% revenue growth and strong EBITDA of $2.43 billion, exceeding industry averages.

26 Jun 2026, 20:05 UTC

Social Media
News
Correlated Moves

Shares of Alphabet Inc. are trading lower amid concerns about Waymo's impact on competitors, as noted in a recent BTIG analysis.

26 Jun 2026, 20:05 UTC

Social Media
News

Microsoft shares are higher amid a market rally, fueled by Michael Burry's bullish sentiment and a valuation surpassing $2.75 trillion.

26 Jun 2026, 20:04 UTC

News

Bank of America Securities reiterated its Buy rating on Ulta Beauty, setting a price target of $685 after a meeting with company executives. Shares are higher today.

26 Jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Intel Corp shares are declining as the semiconductor sector faces pressure. High trading volume reflects increased investor activity amid mixed social media sentiment.

26 Jun 2026, 20:02 UTC

News
Correlated Moves
Social Media

Applied Materials Inc shares are lower amid a decline in the Semiconductor Materials & Equipment sector, despite recent price target increases from analysts.

26 Jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, influencing economic perceptions. Vanguard Total Bond Market ETF is higher since Thursday's close.

26 Jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, potentially impacting economic perceptions and Federal Reserve interest rate decisions.

26 Jun 2026, 19:52 UTC

Correlated Moves
News
Social Media

Broadcom Inc shares fell to $370.12, a 10-week low, amid a broader downturn in the semiconductor sector and negative investor sentiment.

26 Jun 2026, 19:52 UTC

Social Media
News

Qualcomm Inc's stock is lower amid concerns over competition and supply shortages following its new chip architecture announcements for smartphones and data centers.

26 Jun 2026, 19:52 UTC

Social Media
News
Correlated Moves

NVIDIA Corp shares are declining as Amazon Web Services raises GPU prices, potentially reducing demand. Market focus shifts to memory stocks amid broader pressures.

26 Jun 2026, 19:52 UTC

News

Costco Wholesale shares advanced following an insider sale of 885 shares for $847,345 and strong revenue growth of 11.58% over the past three months.

26 Jun 2026, 19:51 UTC

News

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

26 Jun 2026, 19:46 UTC

News
Correlated Moves
Social Media

Meta Platforms is advancing as it accelerates its shift to generative AI for content moderation, despite concerns about compliance and valuation compared to peers.

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

27.09% upside

12 Months Forecast

Average 32.18 USD  27.09%

High 38 USD

Low 23 USD

Based on 13 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Sentiment

By Acuity

68 / 342 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat